Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis

NCT01506362 | Completed Phase 2 Results

• 1 other identifier: BL-7040.01
• Study Type: interventional
• Target: 22
• Locations: 1 country
• Sites: 5

Brief Summary

The objective of the proposed study is to determine whether BL-7040 demonstrates clinical efficacy in patients with inflammatory bowel disease (IBD).

Conditions

Ulcerative Colitis

Keywords

Ulcerative Colitis; IBD

Outcome Measures

Primary Outcomes (1)

• Proportion of Patients Who After Study Completion Achieve Clinical Response Defined by at Least a 3point Decrease & 30% Reduction From Baseline in Mayo Score Plus ≥ 1 Point Decrease in Rectal Bleeding Sub-score or Absolute Rectal Bleeding Subscore of ≤ 1

  Mayo score assesses stool frequency, rectal bleeding, endoscopic findings, and physician's global assessment. It is assessed according to the following parameters: Stool frequency (subscore 0-3) 0: Normal number of stools for patient 1. 1 to 2 stools per day more than normal 2. 3 to 4 stools more than normal 3. \> or = to 5 stools more than normal Rectal bleeding (subscore 0-3) 0: No blood seen 1. Streaks of blood with stool less than half the time 2. Obvious blood with stool most of the time 3. Blood alone passes Endoscopic findings (subscore 0-3) 0: Normal or inactive disease 1 Mild Disease (erythema, decreased vascular pattern, mild friability) 2: Moderate Disease (marked erythema, lack of vascular pattern, friability erosions) 3: Severe Disease (spontaneous bleeding, ulceration) Physician's Global Assessment (subscore 0-3) 0: Normal 1. Mild disease 2. Moderate disease 3. Severe disease

  From Baseline to day 34 (end of treatment period)

Secondary Outcomes (1)

• Proportion of Patients With Mucosal Healing After Completion of Study Treatment Defined as Reduction in Endoscopy Subscore of ≥ 1 From Baseline & an Absolute Endoscopy Subscore of ≤ 1 Assessed by Flexible Sigmoidoscopy.

  5 weeks following first administration

Study Arms (1)

A synthetic oligonucleotide for treatment of IBD.

EXPERIMENTAL

BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.

Drug: BL-7040

Interventions

BL-7040 DRUG

BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems. Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up. BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days.

A synthetic oligonucleotide for treatment of IBD.

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female, age 18 to 70.
• Moderately active ulcerative colitis as defined by Mayo score of ≥ 5 and ≤ 9 within 9 days of first day of study treatment.
• Diagnosis of ulcerative colitis ≥ 3 months prior to study entry.
• Endoscopic sub-score of ≥ 2 and rectal bleeding sub-score of ≥ 1 on the Mayo score and endoscopic evidence of disease activity a minimum of 20 cm from the anal verge, determined within 9 days of first day of study treatment.
• Female patients must have a negative serum pregnancy test at screening and be willing and able to use a medically acceptable method of birth control or declare that they are abstaining from sexual intercourse, from the screening visit through the study termination visit or be surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or post-menopausal. Postmenopausal women are defined as women with menstruation cessation for 12 consecutive months prior to signing of the informed consent form.
• Ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment

You may not qualify if:

• Diagnosis of indeterminate colitis or clinical findings suggestive of Crohn's disease.
• Subjects with ulcerative proctitis.
• A diagnosis of ischemic colitis, fulminant colitis or toxic megacolon.
• Evidence of bowel infection.
• Body temperature ≥ 38°C at screening.
• Evidence of abdominal abscess at the initial screening visit.
• Extensive colonic resection, subtotal or total colectomy.
• Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine.
• Receiving non-permitted IBD therapies
• History of or current peptic ulcer disease.
• Pregnant or lactating women.
• Chronic hepatitis B or C infection or HIV seropositivity.
• Current or recent history of severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurological disease.
• Drug or alcohol abuse (by history).
• Patients participating in any other clinical trials.

Sponsors & Collaborators

• BioLineRx, Ltd.: lead

Study Sites (5)

Soroka Medical Center

Beersheba, Israel

Location

Rambam Medical Center

Haifa, Israel

Location

Hadassah medical center

Jerusalem, Israel

Location

Shaare Zedek Medical center

Jerusalem, Israel

Location

Sourasky Medical Center

Tel Aviv, Israel

Location

MeSH Terms

Conditions

Colitis, Ulcerative

Condition Hierarchy (Ancestors)

Colitis; Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Inflammatory Bowel Diseases; Colonic Diseases; Intestinal Diseases

Results Point of Contact

• Title: Dr. Arnon Aharon
• Organization: BioLineRx LTD

arnona@biolinerx.com

972-2-548-9100

Study Officials

• Sigal Fishman, MD

  Sourasky Medical Center

  PRINCIPAL INVESTIGATOR

• Eran Israeli, MD

  Hadassah Medical Organization

  PRINCIPAL INVESTIGATOR

• Yehuda Chowers, MD

  Rambam Health Care Campus

  PRINCIPAL INVESTIGATOR

• Eran Goldin, MD

  Shaare Zedek Medical Center

  PRINCIPAL INVESTIGATOR

• Alex Fisch, MD

  Soroka University Medical Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 3, 2012
• First Posted: January 10, 2012
• Study Start: March 1, 2012
• Primary Completion: May 1, 2013
• Study Completion: May 1, 2013
• Last Updated: July 15, 2014
• Results First Posted: May 1, 2014

Record last verified: 2014-03

Locations

IL (5)